Cumberland announces strategic Talicia arrangements with RedHill

Rhea-AI Filing Summary

Cumberland Pharmaceuticals (CPIX) reported a strategic arrangement with RedHill Biopharma to jointly commercialize Talicia, an FDA-approved oral capsule for treating Helicobacter pylori infection in adults. The product targets a bacterial infection that is a leading risk factor for gastric cancer.

The company furnished a related press release as Exhibit 99.1 dated October 21, 2025. This update was disclosed under Item 8.01 (Other Events).

Insights

Biopharma Commercial Strategy Analyst

Cumberland and RedHill agree to jointly commercialize FDA‑approved Talicia; impact hinges on undisclosed deal terms and execution.

Cumberland Pharmaceuticals disclosed strategic arrangements with RedHill Biopharma to jointly commercialize Talicia, an FDA‑approved oral capsule for Helicobacter pylori in adults. Joint commercialization typically means shared promotion and distribution efforts, which can expand reach for an approved therapy. This can support broader market access for the product without development risk.

The disclosure does not include economic terms, scope, or responsibilities. Key factors—such as any exclusivity, territories, cost‑sharing, revenue split, and duration—are not provided. Without those details, the financial impact is uncertain. The furnished press release (Exhibit 99.1, dated October 21, 2025) may offer context, but the 8‑K itself limits visibility into magnitude and timing.

Watch for a definitive agreement filing (often under Item 1.01) that specifies economics and obligations, and for any commercialization milestones or guidance updates following October 2025. Track any disclosed timelines for sales efforts and how responsibilities are divided between the companies across channels and geographies over the next few quarters.

0001087294false00010872942025-10-212025-10-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

October 21, 2025 (October 21, 2025)

Date of Report (date of earliest event reported)

CUMBERLAND PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Tennessee			001-33637						62-1765329
(State or other jurisdiction of incorporation or organization)			(Commission File Number)						(I.R.S. Employer Identification No.)

1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203

(Address of Principal Executive Offices)

(615) 255-0068

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, no par value			CPIX			NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01     Other Events

On October 20, 2025, Cumberland Pharmaceuticals Inc. (“Cumberland”) announced strategic arrangements with RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer.

A copy of the release is furnished as Exhibit 99.1.

Exhibit No.						Description
99.1						Press release dated October 21, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

Dated: October 21, 2025

By:

/s/ John Hamm

John Hamm

Chief Financial Officer

FAQ

What did Cumberland Pharmaceuticals (CPIX) announce?

Cumberland announced strategic arrangements with RedHill Biopharma to jointly commercialize Talicia.

Which product is covered by the CPIX–RedHill arrangement?

Talicia, an FDA-approved oral capsule for treating Helicobacter pylori infection in adults.

What condition is Talicia indicated to treat?

Talicia is indicated for Helicobacter pylori infection in adults, a leading risk factor for gastric cancer.

Where can I find more details on the CPIX announcement?

A press release was furnished as Exhibit 99.1 dated October 21, 2025.

What SEC form did CPIX file for this update?

An 8-K under Item 8.01 (Other Events).

Who is Cumberland’s partner in this arrangement?

RedHill Biopharma Ltd. (Nasdaq: RDHL).